Comparing Cue Biopharma (CUE) and Its Rivals

Cue Biopharma (NASDAQ: CUE) is one of 564 public companies in the “Pharmaceutical preparations” industry, but how does it weigh in compared to its peers? We will compare Cue Biopharma to similar companies based on the strength of its institutional ownership, analyst recommendations, earnings, valuation, profitability, risk and dividends.

Risk and Volatility

Cue Biopharma has a beta of 1.16, meaning that its stock price is 16% more volatile than the S&P 500. Comparatively, Cue Biopharma’s peers have a beta of 1.30, meaning that their average stock price is 30% more volatile than the S&P 500.


This table compares Cue Biopharma and its peers’ net margins, return on equity and return on assets.

Net Margins Return on Equity Return on Assets
Cue Biopharma -3,233.51% -116.05% -90.83%
Cue Biopharma Competitors -1,496.32% -853.06% -29.84%

Analyst Ratings

This is a summary of current ratings and price targets for Cue Biopharma and its peers, as provided by MarketBeat.

Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Cue Biopharma 0 0 1 0 3.00
Cue Biopharma Competitors 4833 13651 28514 1036 2.54

Cue Biopharma presently has a consensus target price of $14.50, suggesting a potential upside of 68.60%. As a group, “Pharmaceutical preparations” companies have a potential upside of 63.55%. Given Cue Biopharma’s stronger consensus rating and higher possible upside, analysts clearly believe Cue Biopharma is more favorable than its peers.

Institutional & Insider Ownership

16.6% of Cue Biopharma shares are owned by institutional investors. Comparatively, 46.0% of shares of all “Pharmaceutical preparations” companies are owned by institutional investors. 18.6% of Cue Biopharma shares are owned by company insiders. Comparatively, 15.4% of shares of all “Pharmaceutical preparations” companies are owned by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock will outperform the market over the long term.

Earnings & Valuation

This table compares Cue Biopharma and its peers gross revenue, earnings per share and valuation.

Gross Revenue Net Income Price/Earnings Ratio
Cue Biopharma $1.14 million -$38.98 million -4.43
Cue Biopharma Competitors $2.12 billion $221.77 million -3.84

Cue Biopharma’s peers have higher revenue and earnings than Cue Biopharma. Cue Biopharma is trading at a lower price-to-earnings ratio than its peers, indicating that it is currently more affordable than other companies in its industry.


Cue Biopharma peers beat Cue Biopharma on 8 of the 13 factors compared.

About Cue Biopharma

Cue Biopharma, Inc., a biopharmaceutical company, develops biologic drugs for the selective modulation of the human immune system to treat a range of cancers, chronic infectious diseases, and autoimmune disorders. Its lead drug candidate CUE-101, a protein biologic designed to target and activate antigen-specific T cells for human papilloma virus driven cancers. The company offers CUE-102, a non-viral antigen for cancers; CUE-103, an antigen; CUE-200 framework that includes CD80 and/or 4-1BBL to reactivate exhausted T cells and design to enhance antigen-specific T cell for the treatment of chronic infectious diseases; and CUE-300 framework to target various autoimmune diseases. It has collaboration agreements with Merck Sharp & Dohme Corp. for the research and development of its proprietary biologics that target various autoimmune disease indications; LG Chem Life Sciences for Immuno-selective targeting and alteration of T cells (STAT) in the field of oncology; and Albert Einstein College of Medicine to develop Immuno-STAT biologics for chronic infectious diseases. The company was formerly known as Imagen Biopharma, Inc. and changed its name to Cue Biopharma, Inc. in October 2016. Cue Biopharma, Inc. was incorporated in 2014 and is headquartered in Cambridge, Massachusetts.

Receive News & Ratings for Cue Biopharma Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Cue Biopharma and related companies with's FREE daily email newsletter.